SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA) today announced that Dr. Graeme Moyle, Director of HIV
Research, Chelsea and Westminster Hospital, will present results from the
Phase 2a proof-of-concept monotherapy study of RDEA806, during an oral
presentation at a late breaker session of the XVII International AIDS
Conference in Mexico City on August 7, 2008. RDEA806 is the Company's novel
investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for
patients with human immunodeficiency virus (HIV).
Date/Time: Thursday, August 7, 2008 from 2:30 p.m. - 4:00 p.m. CDT
Abstract Title: "Antiviral activity of RDEA806, a novel HIV non-nucleoside
reverse transcriptase inhibitor, in treatment of naive HIV patients"
Session Title: THAB04 - Late Breaker Track B, Session 2
Location: Centro Banamex -- Session Room 1 (Abstract #THAB0403)
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, cancer and inflammatory diseases,
including gout. We have four drug candidates in clinical trials and others
in preclinical development and discovery. Our most advanced development
candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor
(NNRTI), which has successfully completed a Phase 2a study for the
treatment of patients with HIV. We have evaluated our second-generation
NNRTI for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it as a development candidate.
RDEA594, our lead development candidate for the treatment of gout, is in
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved